Hyland's Cough and Cold Medicines Remain a Safe and Effective Option for Toddlers and Youn... (ions contact a physician pharmacist or o...)

Hyland's Cough and Cold Medicines Remain a Safe and Effective Option for Toddlers and Young Children

Date:1/18/2008

ions contact a physician, pharmacist or other health care professional to discuss how to treat a child with a cough or cold.

Homeopathic medicines continue their long history of safety and are still available at retail stores. For more information about all Hyland's homeopathic medicines, log on to http://www.hylands.com.

Hyland's understands what busy families need to stay healthy. Hyland's develops homeopathic formulas with the highest quality natural ingredients following the strictest of standards for preparation. With a century of commitment, Hyland's tradition of excellence consistently provides quality and integrity in every product. From Hyland's Teething Tablets to Hyland's Calms Forte, Hyland's cares for your family at every stage of life. Consumers can trust all Hyland's products to be natural, gentle, effective and safe for the entire family.

SOURCE Hyland?s, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. FDA Cracks Down on Unapproved Cough Medicines
2. McNeil Consumer Healthcare is Voluntarily Withdrawing Infants Cough and Cold Products:
3. Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines
4. CVS/pharmacy to Remove OTC Infant Cough & Cold Products from Its Stores as Part of CHPAs Voluntary Withdrawal
5. Drug Makers Withdraw Cough, Cold Meds for Infants
6. Stop & Shop Removes Childrens Cough and Cold Medicine from Store Shelves
7. Giant Food Removes Childrens Cough and Cold Medicine From Store Shelves
8. Reflux Can Precipitate Chest Pain, Cough
9. Statement from the Consumer Healthcare Products Association on Todays Joint FDA Advisory Committee Recommendations Regarding Pediatric Over-the-Counter Cough and Cold Medicines
10. Honey Beats Meds at Soothing Kids Cough
11. Chronic Coughs Need a Doctors Attention

Post Your Comments:

(Date:11/27/2009)... cycling plus low-emission vehicles may reduce fut...FRIDAY, Nov. 27 (HealthDay News) -- Encouraging ci...ars would offer much greater public health benefit...K. researchers have found. , The study compared...ve urban land transport scenarios for London, Engl...

(Date:11/27/2009)... Specialist manufacturers who use me...e saving millions of dollars by bringing in techno...Increasing numbers of pro-active medical manufactu...he concept stage of their projects, ensuring that ...n processes or potentially outdated technology. ,...

(Date:11/26/2009)...r sequestering drug tetrathiomolybdate (TM) has be...nt of Wilson disease, a disease caused by an overl...t much is known. Very little, however, is known ab... A new study led by Northwestern University resear...ee-dimensional structure of TM bound to copper-loa...

(Date:11/26/2009)... Research Triangle Dental (RTDental)... Carolina, today announced the expansion of its se...R Dentist, Dr. Doug Macmillan. , ... Dental is pleased to announce that Dr. Doug Macmi... completed an additional advanced training seminar...

(Date:11/25/2009)..., EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCa... ) today announced that the company will host two ... ,, December 7, 2009 - 9:00 a.m. CT/10:00 a...s data presentations surrounding carfilzomib in re...ured at the 51st American Society of Hematology (A...

Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2 Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2 Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3 Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4 Health News:Research sheds light on workings of anti-cancer drug 2 Health News:Research sheds light on workings of anti-cancer drug 3 Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2 Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2

[0] More Foot Power, Less Car Pollution Best for Health [0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells [1] Research sheds light on workings of anti-cancer drug [0] Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental [0] Onyx Pharmaceuticals Announces December 2009 Investor Events

...o protect all, studies show shots cut deaths, hosp...y News) -- The more people who get the flu vaccine...new studies. , In the first study, researchers fro...nce in 2000 helped lower flu-related deaths, hospi...

...ation and International Business Drive Top-Line Gr...er of Profitability, WESTFORD, Mass., Oct. 28 Cy... and manufacturer of a broad array of,light-based ...Results, Revenues increased to $38.2 million for ...

...nted Sunday, November 2, 2008 at this year,s liver... 31 - November 4, SAN FRANCISCO, Oct. 28 Researc..., led by Jennifer Kramer, Ph.D., looked at a,popul...us patients who have HIV are treated for HCV. This...

...., Oct. 28 Frost & Sullivan is,pleased to announc...ts 2008,Excellence in Healthcare Innovation Awards...at will take place on November 12, 2008 in San Ant...thcare.,Such companies have shown success at meeti...

...utive team has extensive medical device and financ...AIN VIEW, Calif., Oct. 28 PolyRemedy, Inc., a,man... fabrication and,tracking of customized, nano-mate... on October 14, 2008, and reports,directly to the ...

...NSUMERS LOOK TO MINIMALLY-INVASIVE PROCEDURES, CH...ooks matter for everyone from presidential candida...s forcing many consumers to re-evaluate,their cosm...ic meeting of the American Society of Plastic Surg...

When It Comes to Flu, the More Who Get Vaccine, the Better Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008 Why Are Some Veterans Who Are Coinfected With Hepatitis C and HIV More Likely to Be Treated for HCV Than Others?Frost & Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards PolyRemedy Hires Gary Coughlen as CFO Consumers and Plastic Surgeons Say Economy Is Cutting Into Cosmetic Procedures

(Date:11/25/2009)....C., Nov. 25 Cempra Pharmaceutical... president and chief executive officer, will prese...nference at 8:50 a.m. EST, December 1, 2009, at Th...nandes will provide an overview of the company,s t...eatment of drug-resistant pathogens including MRSA...

(Date:11/25/2009)...Netherlands and JOHANNESBURG, November 25 /PRNewsw...and Pyxis Discovery announced today,that they have...t both,companies, services. , Pyxis,s wor...y expertise,will be coupled with iThemba,s service...stry support to projects identified through Pyxis,...

(Date:11/24/2009)... Md., Nov. 24 /PRNewswire-Asia/ -- Chindex Interna...ng independent American provider of Western,health...c of China, today,announced that the Company will ...ealth Care Conference, to be held December 1 - 2, ...agement is currently scheduled to present at 11:30...

Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2 Chindex International to Present at Piper Jaffray Health Care Conference 2 Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 55983 1 Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 55983 2 Pharmavite Pilots LearnSomething Interactive Digital Signage to Reach Shoppers in Stores 55983 3 VisEn Launches New Annexin Vivo 750 Fluorescence Molecular Imaging Agent 13792 1 VisEn Launches New Annexin Vivo 750 Fluorescence Molecular Imaging Agent 13792 2 VisEn Launches New Annexin Vivo 750 Fluorescence Molecular Imaging Agent 13792 3 Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 1 Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 2 Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 3 Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 4 Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara 28R 29 for Treatment of Brain Ca 4935 5

[0] Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference [0] iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering [0] Chindex International to Present at Piper Jaffray Health Care Conference

...ts with multiple sclerosis, remained relapse-fre...- New data demonstrate 89% of patients free from a...S - three years after starting treatment, - MS, a...y, affects 2.5 million people worldwide i...lings planned before end of 2009 in US and EU, EA...

...sis of methotrexate,resistance and differences in ...The first analysis,of the genetic determinants of ... childhood acute lymphoblastic leukemia (ALL) coul...d treatments to overcome it,according to a St. Jud...s use in ALL, methotrexate is widely used to treat...

Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6 St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2 St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3 St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia

ExcaliburPlus PC, 220V, 50Hz

Elmed BC 50 Standard

Hudson Burr

Cushing Burr

Medicine Products:

ExcaliburPlus PC, 220V, 50Hz Elmed BC 50 Standard Hudson Burr Cushing Burr

Hyland's Cough and Cold Medicines Remain a Safe and Effective Option for Toddlers and Youn...(ions contact a physician pharmacist or o...),Health